Hospira (HSP)

Q3 2011 Earnings Call

October 26, 2011 9:00 am ET


Thomas E. Werner - Chief Financial Officer and Senior Vice President of Finance

Sumant Ramachandra - Chief Scientific Officer and Senior Vice President of Research & Development & Medical Affairs

Karen King - Vice President Investor Relations

Michael Michael Ball - Chief Executive Officer, Director and Member of Science, Technology & Quality Committee


Gregory Hertz - Citigroup Inc, Research Division

Robert M. Goldman - CL King & Associates, Inc.

Gregory B. Gilbert - BofA Merrill Lynch, Research Division

Frederick A. Wise - Leerink Swann LLC, Research Division

Jessica Fye - JP Morgan Chase & Co, Research Division

Jayson T. Bedford - Raymond James & Associates, Inc., Research Division

Matthew Taylor - Barclays Capital, Research Division

David H. Roman - Goldman Sachs Group Inc., Research Division

Shibani Malhotra - RBC Capital Markets, LLC, Research Division

Marshall Urist - Morgan Stanley, Research Division

David G. Buck - Buckingham Research Group, Inc.

Louise A. Chen - Collins Stewart LLC, Research Division



Welcome to Hospira's Third Quarter 2011 Conference Call. [Operator Instructions] I will now turn the call over to Karen King, Vice President of Investor Relations. Karen, you may now begin your conference.

Karen King

Thank you. Good morning, everyone, and welcome to our conference call and webcast regarding Hospira's financial results for the third quarter of 2011. Participating in today's call are Mike Ball, Chief Executive Officer of Hospira; Tom Werner, Senior Vice President of Finance and Chief Financial Officer; Sumant Ramachandra, Senior Vice President and Chief Scientific Officer, will also be joining us for Q&A.

If you liked this article you might like

New Lifetime High For Hospira (HSP)

Hospira (HSP) Showing Signs Of Being Strong And Under The Radar

Trade-Ideas: Hospira (HSP) Is Today's New Lifetime High Stock

10 Best S&P 500 Health Care Stocks

10 Best S&P 500 Stocks This Year